The authors hypothesized that an increased CCL16 might reduce liver cirrhosis through inactivating hepatic stellate cells which, although beneficial in liver cirrhosis, would not be beneficial in attenuating the progression of renal disease. This evidence concerns the gene CCL16 and cirrhosis of liver.